SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

13 Feb 2024 Evaluate
The sales for the December 2023 quarter moved up 39.72% to Rs. 2413.64 millions as compared to Rs. 1727.48 millions during the corresponding quarter last year.The Net proft of the company remain more or less same to Rs. 252.87  millions from Rs. 256.22 millions ,decline by -1.31%.OP of the company witnessed a marginal growth to 433.00 millions from 395.30 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 2413.64 1727.48 39.72 6280.78 5021.59 25.08 6552.04 6582.89 -0.47
Other Income 13.25 157.14 -91.57 498.79 561.80 -11.22 604.82 422.51 43.15
PBIDT 433.00 395.30 9.54 1559.11 1253.74 24.36 1523.85 1559.66 -2.30
Interest 2.67 8.48 -68.51 7.60 29.56 -74.29 36.13 37.95 -4.80
PBDT 430.33 386.82 11.25 1551.51 1224.18 26.74 1487.72 1521.71 -2.23
Depreciation 84.34 41.79 101.82 216.56 132.27 63.73 167.37 176.63 -5.24
PBT 345.99 345.03 0.28 1334.95 1091.91 22.26 1320.35 1345.08 -1.84
TAX 93.12 88.81 4.85 327.28 241.34 35.61 291.69 305.20 -4.43
Deferred Tax -4.44 1.56 -384.62 37.86 2.50 1414.40 -1.71 5.04 -133.93
PAT 252.87 256.22 -1.31 1007.67 850.57 18.47 1028.66 1039.88 -1.08
Equity 453.16 402.96 12.46 453.16 409.31 10.71 453.16 409.31 10.71
PBIDTM(%) 17.94 22.88 -21.60 24.82 24.97 -0.57 23.26 23.69 -1.84

Marksans Pharma Share Price

179.55 -0.95 (-0.53%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×